Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally.
The last earnings update was 7 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Kuros Biosciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Kuros Biosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Kuros Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
Kuros Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Kuros Biosciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Kuros Biosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Kuros Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Kuros Biosciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Kuros Biosciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Kuros Biosciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Prof. Joost D. de Bruijn, B.Sc. Ph.D., has been Chief Executive Officer of Kuros Biosciences AG since December 4, 2017 and its Director since June 14, 2018. Prof. Dr. de Bruijn served as the Chief Executive Officer and President of Xpand biotechnology BV until 2017. Prof. Dr. de Bruijn Founded Xpand Biotechnology BV in 2004. Mr. de Bruijn is Co-Owner of Aldabra B.V. He founded Progentix Orthobiology B.V. in 2004 and served as its Chief Executive Officer and President. He directed the Bone Tissue Engineering programme at IsoTis SA and showing safety of the technology in feasibility clinical trials. He has more than 28 years experience in academia and the life science industry. He has ample experience in bone tissue engineering, adult stem cell culturing techniques and the development of calcium phosphate scaffolds. He holds the Chair in Biomaterials at the Department of Materials of Queen Mary University of London, UK. He also holds the positions of professor of biomaterials at Queen Mary University of London (UK) and professor of regenerative medicine and entrepreneurship at Twente University (NL). He has published 165 papers in peer-reviewed journals and is the inventor of 24 patent families. He is scientific editor and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. He obtained his PhD from Leiden University in 1993, The Netherlands and spent part of his time at the Centre for Biomaterials, University of Toronto, Canada.
Insufficient data for Joost to compare compensation growth.
Insufficient data for Joost to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Kuros Biosciences management team is less than 2 years, this suggests a new team.
Chief Development Officer
Frank-Jan van der Velden
Head of Business Affairs & Finance of Kuros Biosciences BV
Joost de Bruijn
CEO & Director
Chief Financial Officer
Senior Legal Counsel
Chief Business Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Kuros Biosciences board of directors is less than 3 years, this suggests a new board.
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion; and KUR-112 that consists of a natural healing matrix combined with a targeted bone growth factor intended to be applied as a single percutaneous injection into solitary bone cysts. The company has collaborations with Checkmate Pharmaceuticals LLC for the licensing of CYT003 for the treatment of oncology; Pfizer Inc. to develop a novel anti-IgE vaccine; and Singapore’s Agency for Science, Technology and Research, which researches, develops, and commercializes an influenza vaccine. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.